B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $460 to $410.